Floatz logo

Cnto 1275

Multiple Sclerosis

Centocor, Inc.Phase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

183 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB

View all 50 →

Same molecule, other indications

Cnto 1275 is also rated in:

primary biliary cholangitisDormant
B
Indicative ·
57 / 100
View asset →
diarrhea, glucose-stimulated secretory, with common variable immunodeficiencyDormant
CCC
Indicative ·
52 / 100
View asset →
Alzheimer diseaseDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →